Trial Profile

TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tazemetostat (Primary)
Indications Chordoma; CNS cancer; Renal cancer; Rhabdoid tumour; Sarcoma; Teratoma
Focus Adverse reactions
Acronyms TAZNI

Most Recent Events

13 Apr 2026 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
20 Jun 2023 Planned initiation date changed from 1 Jun 2023 to 15 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com